The North America Whole Exome Sequencing (WES) market is experiencing robust growth, propelled by increasing applications in clinical diagnostics, personalized medicine, and genomic research. Rapid advances in sequencing technology and growing investments by key industry players are driving the adoption of WES across healthcare settings in the region. With ongoing innovation and favorable regulatory environments, the market is poised for sustained expansion from 2024 to 2035.
The economic impact of tariffs on "North America Whole Exome Sequencing Market".
Market Growth Drivers
Rise in Precision Medicine and Genetic Testing: The demand for personalized therapies has triggered a substantial increase in genetic and genomic testing, especially in oncology and rare disease diagnostics. Companies such as Illumina Inc. are expanding their portfolio with advanced whole exome sequencing workflows to support clinical applications, enabling faster and more accurate identification of disease-causing mutations. As hospitals and diagnostic labs prioritize next-generation sequencing (NGS) techniques, the reliance on WES is expected to escalate, resulting in greater adoption across North America.
Technological Innovations for Higher Accuracy and Lower Costs: Continuous advancements in sequencing chemistry, bioinformatics, and automation have helped reduce the cost per exome while improving sequencing depth and accuracy. Thermo Fisher Scientific, for example, introduced proprietary exome enrichment kits that enable faster turnaround and higher detection sensitivity, which supports broader deployment in both research and clinical practices. These improvements are catalyzing wider inclusion of exome sequencing in routine diagnostic workflows, driving market growth.
Market Trends
Integration of Artificial Intelligence (AI) in Data Analysis: AI and machine learning tools are increasingly being leveraged to interpret massive exome datasets with greater speed and precision. Companies like Agilent Technologies have launched AI-powered platforms that help clinicians and researchers rapidly identify disease-associated variants, minimizing diagnostic turnaround time. This trend is enhancing efficiency across genomic laboratories and promoting wider use of WES.
Clinical Partnerships and Expansion of Service Offerings: The trend of strategic collaborations between diagnostic laboratories, healthcare institutions, and sequencing firms is driving innovation in the North American WES market. For instance, partnerships between Quest Diagnostics and academic medical centers have resulted in expanded access to clinical exome sequencing for undiagnosed diseases, ultimately improving patient care and supporting the commercialization of new bioinformatics solutions.
Market Opportunity
Expansion into Pharmacogenomics: With increasing focus on pharmacogenomics for optimizing therapeutic interventions, WES presents an opportunity for biopharma companies such as Roche and Pfizer to integrate sequencing-based insights into drug development and patient stratification, resulting in personalized and safer treatments.
Penetration in Emerging Clinical Segments: The growing awareness and adoption of whole exome sequencing in areas like pediatric medicine, infectious diseases, and neurological disorders offer significant opportunities for market participants to expand their service portfolios and reach a larger customer base.
North America Whole Exome Sequencing Market Revenue (2020-2035)
The market revenue for the North America Whole Exome Sequencing Market demonstrates a remarkable upward trajectory from 2020 to 2035. Starting at USD 580 million in 2020, the market witnessed rapid adoption due to technological advancements and healthcare integration, reaching USD 1,020 million by 2025. The compounded annual growth rate (CAGR) of approximately 12.7% illustrates sustained and aggressive investments in precision medicine and genomic research. By 2035, revenue is forecasted to exceed USD 3,700 million, reflecting the market’s maturity and the expansion of exome sequencing applications beyond clinical diagnostics into areas like drug development and population health.
North America Whole Exome Sequencing Market Share by Region, 2025
In 2025, the United States commands the largest share of the North American Whole Exome Sequencing Market, accounting for 72%, driven by its advanced healthcare infrastructure, research investments, and high adoption rates among leading academic and clinical institutions. Canada follows with a 20% share, reflecting significant government funding and expansion of genomics research. Mexico, though emerging, holds 5%, while the combined share of rest of North America—including Puerto Rico and others—accounts for 3%. This distribution highlights the dominance of the U.S. but underscores opportunities for growth in neighboring regions as awareness and investment continue to rise.
Recent Developments
In March 2024, Illumina, Inc. announced the release of the NovaSeq X Plus platform in North America, which boosts throughput for whole exome sequencing while reducing run times by 30%. The platform’s launch marks a strategic move by Illumina to capture both clinical and research demand, providing greater access to large-scale sequencing projects.
In May 2024, Thermo Fisher Scientific entered a strategic partnership with the Canadian institution Genome Canada to accelerate the adoption of WES in rare disease diagnostics. This collaboration includes deploying advanced Ion Torrent sequencing systems and bioinformatics pipelines tailored for the unique regulatory requirements of the Canadian market.
In April 2024, Agilent Technologies launched a next-generation exome enrichment kit, SureSelect Human All Exon V9, aimed at increasing target capture efficiency and data accuracy in clinical exome sequencing workflows. The product launch emphasizes Agilent’s continued R&D investment and focus on supporting translational genomics and precision medicine initiatives in North America.
Sequencing by Synthesis, Ion Semiconductor Sequencing, Single Molecule Real Time Sequencing, Nanopore Sequencing, Pyrosequencing, Others; Diagnostics, Drug Discovery, Personalized Medicine, Agriculture & Animal Research, Biomarker Discovery, Others
Press Releases